<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pruritus associated with cholestasis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pruritus associated with cholestasis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pruritus associated with cholestasis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raoul Poupon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith D Lindor, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cholestasis is seen with many hepatobiliary disorders that produce extrahepatic biliary obstruction and/or intrahepatic biliary disruption. One particularly troublesome symptom associated with cholestasis is pruritus, which can range in severity from mild, to moderate (in which sleep is disturbed), and to extreme (in which the lifestyle of the patient is completely disrupted). </p><p>This topic will review the pathogenesis, clinical manifestations, diagnosis, and management of cholestasis-associated pruritus. The disorders associated with cholestasis are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"</a> and  <a class="medical medical_review" href="/z/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury"</a> and  <a class="medical medical_review" href="/z/d/html/2500.html" rel="external">"Clinical manifestations and diagnosis of cholangiocarcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis"</a>.)</p><p>The following discussion is consistent with guidelines from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aasld.org%2Fsites%2Fdefault%2Ffiles%2F2022-04%2FPracticeGuidelines-PBC-November2018_1.pdf&amp;token=xc90Adx1EnhbWlyu5kG8A9C8wsqThXYq5CFNdRlfL%2BJmoiwaqKCnJX7u4CI4eP0QMwJc2a8EovH5C7dQrWzqgWrMNJN50%2F%2B6bGG%2B5VCIMGOxsCrRn3agDbbFHHbHYFXe&amp;TOPIC_ID=3607" target="_blank">American Association for the Study of Liver Diseases</a> and the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0168827809003092&amp;token=kfDaku7Z%2BKfeT5fgXqtcyMn0Pz2Hqdpq6bC8AyA%2F9SYDjnqbtF0zXz3UYFTG93rXvm7DwKOO1BVIFSgWrFagSoQ5SCOLt8Swr4ZZ9AaonfY%3D&amp;TOPIC_ID=3607" target="_blank">European Association for the Study of the Liver</a> [<a href="#rid1">1</a>] on the management of primary biliary cholangitis (previously referred to as primary biliary cirrhosis) and cholestatic liver disease, respectively.</p><p class="headingAnchor" id="H71722299"><span class="h1">ASSOCIATED CONDITIONS</span><span class="headingEndMark"> — </span>Pruritus may develop in patients with cholestasis due to any cause. It may be seen with primary biliary cholangitis (previously referred to as primary biliary cirrhosis), primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, biliary obstruction, chronic viral hepatitis, cirrhosis, prolonged drug-induced cholestasis, and inherited cholestasis syndromes (eg, progressive familial intrahepatic cholestasis and benign recurrent intrahepatic cholestasis [<a href="#rid2">2</a>]).</p><p>The frequency with which pruritus is seen in these conditions is variable [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intrahepatic cholestasis of pregnancy: 100 percent (pruritus is a prerequisite for making the diagnosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Primary biliary cholangitis: Up to 80 percent by 10 years</p><p class="bulletIndent1"><span class="glyph">●</span>Primary sclerosing cholangitis: 20 to 40 percent of patients at presentation, increasing as the disease progresses</p><p class="bulletIndent1"><span class="glyph">●</span>Malignant biliary tract obstruction: 45 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic viral hepatitis: 20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Nonmalignant biliary tract obstruction: 17 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cirrhosis: 7 percent</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of pruritus in cholestasis is unknown, but several hypotheses have been proposed, including bile acid accumulation, activation of specific neuronal pathways, and elevation in lysophosphatidic acid levels [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Bile acids</span><span class="headingEndMark"> — </span>One theory proposes that elevated levels of bile acid in the skin act as pruritogens. Observations in favor of this theory include the recovery of bile acids from the skin surface of affected patients [<a href="#rid6">6</a>], although the reliability of the methods used to detect the bile acids is uncertain. Other studies have found that administering bile acids can induce pruritus [<a href="#rid7">7,8</a>].</p><p>However, there are three observations that are not consistent with a primary role for bile acids as the cause of pruritus:</p><p class="bulletIndent1"><span class="glyph">●</span>The occasional subsidence of pruritus despite ongoing cholestasis and persistence of elevated plasma bile acid levels [<a href="#rid9">9</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The absence of pruritus in many patients with cholestasis and elevated plasma bile acid levels [<a href="#rid9">9</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The apparent lack of correlation between the presence or severity of pruritus and concentrations of bile acids in skin of patients with chronic cholestasis in the most carefully done study that investigated this question [<a href="#rid10">10</a>]</p><p></p><p>Furthermore, <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> and <a class="drug drug_general" data-topicid="9294" href="/z/d/drug information/9294.html" rel="external">colestipol</a>, agents used to treat the pruritus of cholestasis, also ameliorate pruritus in patients with uremia and polycythemia vera, conditions not associated with bile salt retention. (See <a class="local">'Bile acid sequestrants'</a> below.)</p><p>A related hypothesis implicates elevated plasma bile acids via hepatocyte toxicity, rather than their effect on nerve endings [<a href="#rid11">11</a>]. The detergent bile acids alter hepatocyte membranes, permitting the leakage of hepatocyte contents (some of which are pruritogens) into the bloodstream.</p><p class="headingAnchor" id="H4"><span class="h2">Endogenous opioids</span><span class="headingEndMark"> — </span>There is increasing evidence for an important role for endogenous opioids in the pathogenesis of cholestatic pruritus [<a href="#rid12">12</a>]. The administration of opioid drugs with agonist activity at the mu opioid receptor can produce pruritus in normal individuals, presumably by a central action. More importantly, endogenous opioid levels are elevated (via an uncertain mechanism) in patients with chronic liver disease [<a href="#rid13">13,14</a>], and many reports have shown a reduction in cholestatic pruritus in patients treated with opioid antagonists [<a href="#rid12">12,15-17</a>]. (See <a class="local">'Opioid antagonists'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h2">Lysophosphatidic acid</span><span class="headingEndMark"> — </span>Studies suggest an important role for lysophosphatidic acid (LPA) in cholestatic pruritus [<a href="#rid18">18-20</a>]. LPA is a phospholipid that is formed by the action of autotaxin, which cleaves a choline group from lysophosphatidylcholine. In one study, compared with controls, patients with cholestatic pruritus had significantly increased serum concentrations of LPA and autotaxin activity [<a href="#rid18">18</a>]. In addition, injection of LPA induced a scratch response in mice. (See <a class="local">'Rifampin'</a> below.)</p><p class="headingAnchor" id="H71722306"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Pruritus in patients with cholestasis may be generalized or localized (particularly to the palms of the hands and soles of the feet) [<a href="#rid2">2</a>]. The intensity of the pruritus is variable and it can wax and wane spontaneously. The severity does not correlate with the severity of the underlying liver disease. Pruritus is often worse at night and may be exacerbated by psychologic stress. Females who are premenstrual may also experience a worsening of symptoms. Cool temperatures often lead to improvement. Long-standing scratching may result in excoriations, folliculitis, prurigo nodularis, and lichenification. </p><p>Pruritus can have a profound effect on a patient's quality of life, resulting in sleep deprivation and emotional disturbances (including suicidal ideation in some patients) [<a href="#rid2">2</a>].</p><p>Quantifying the severity of pruritus can be difficult but is important when evaluating the efficacy of medical therapy. Investigators have developed a scratching activity monitoring system that allows for recording of scratching behavior independent from gross body movement, thereby allowing for the inclusion of behavioral methodology in clinical trials of pruritus [<a href="#rid21">21</a>]. Nevertheless, clinical trials have generally been small and used varying scales for measuring pruritus limiting comparison among them [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H71722320"><span class="h1">DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for causes of pruritus is long. However, a presumptive diagnosis of cholestasis-associated pruritus can be made in a patient with cholestasis who complains of itching. An extensive evaluation is generally not required, provided the cause of the cholestasis is known, though patients should have a skin examination to look for evidence of dermatologic disorders associated with pruritus (eg, atopic dermatitis or contact dermatitis). In addition, uremic pruritus should be considered in patients with end-stage kidney disease. If the cause of the cholestasis is not known, the patient should undergo additional evaluation with laboratory tests and imaging studies. (See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Elevated alkaline phosphatase'</a>.)</p><p class="headingAnchor" id="H71722313"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>The intensity of pruritus typically fluctuates over time (both within the day and over longer periods of time). It may lessen with the development of end-stage liver disease. It may also improve with time in patients with primary biliary cholangitis (previously referred to as primary biliary cirrhosis). In females with intrahepatic cholestasis of pregnancy, pruritus often worsens as the pregnancy progresses and then typically resolves within a few days of delivery [<a href="#rid23">23</a>]. Some patients develop severe, refractory pruritus requiring liver transplantation. (See <a class="local">'Pruritus refractory to standard treatment'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H71722334"><span class="h2">Treatment of the underlying disorder</span><span class="headingEndMark"> — </span>The first step in treating patients with cholestasis-associated pruritus is to treat the underlying disease, if possible. The specific treatment will depend on the cause of the cholestasis. Some of the disease-specific treatments include: </p><p class="bulletIndent1"><span class="glyph">●</span>Primary biliary cholangitis (previously referred to as primary biliary cirrhosis): <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">Ursodeoxycholic acid</a></p><p class="bulletIndent1"><span class="glyph">●</span>Primary sclerosing cholangitis: Endoscopic treatment of dominant strictures</p><p class="bulletIndent1"><span class="glyph">●</span>Malignant extrahepatic biliary obstruction: Bile duct stenting</p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced cholestasis: Discontinuation of the offending medication</p><p></p><p class="headingAnchor" id="H71723146"><span class="h2">Treatment of pruritus</span><span class="headingEndMark"> — </span>The treatment of pruritus depends on the severity of symptoms. If symptoms are mild, nonspecific measures (eg, emollients) may help. Moderate to severe pruritus is treated with pharmacologic therapy (eg, <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a>). Severe, refractory pruritus may require liver transplantation.</p><p class="headingAnchor" id="H71723122"><span class="h3">Mild pruritus</span><span class="headingEndMark"> — </span>If the pruritus is mild, treatments such as warm baths and emollients may help. Antihistamines may also be helpful, particularly for patients with insomnia. However, these measures often fail when the pruritus is moderate to severe. </p><p class="headingAnchor" id="H71723128"><span class="h3">Moderate to severe pruritus</span></p><p class="headingAnchor" id="H71725809"><span class="h4">General approach</span><span class="headingEndMark"> — </span>For patients with moderate to severe pruritus who do not respond to nonspecific measures, we begin pharmacologic therapy. </p><p>For patients who do not have primary biliary cholangitis or intrahepatic cholestasis of pregnancy we do the following:</p><p class="bulletIndent1"><span class="glyph">●</span>We initially treat with a bile acid sequestrant such as <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> (total daily dose of 4 to 16 grams). (See <a class="local">'Bile acid sequestrants'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the bile acid sequestrant does not provide adequate, relief we switch to <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (150 to 300 mg twice daily). (See <a class="local">'Rifampin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If symptoms persist, we then switch to an opioid antagonist, such as <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> (12.5 to 50 mg/day). (See <a class="local">'Opioid antagonists'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Switching to <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> (75 to 100 mg daily) or <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> 90 mg at bedtime can be tried if other measures fail. Phenobarbital has the disadvantage of causing somnolence during the first few weeks of use. (See <a class="local">'Sertraline'</a> below and <a class="local">'Pruritus refractory to standard treatment'</a> below.)</p><p></p><p>For treatment of pruritus in patients with primary biliary cholangitis, in addition to <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a>, we suggest treatment with <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a>. We start with a low dose (eg, 200 to 300 mg daily) and then over the next few weeks gradually increase the dose to 13 to 15 mg/kg per day given in two to three divided doses. Bile acid sequestrants should be given two to four hours before or after ingestion of ursodeoxycholic acid (UDCA). For patients with primary biliary cholangitis who do not respond to ursodeoxycholic acid alone, <a class="drug drug_general" data-topicid="8696" href="/z/d/drug information/8696.html" rel="external">bezafibrate</a> can be used in combination with ursodeoxycholic acid [<a href="#rid24">24,25</a>]. (See  <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">"Overview of the management of primary biliary cholangitis", section on 'Pruritus'</a>.)</p><p>Treatment in females with intrahepatic cholestasis of pregnancy must take into account potential adverse effects of the treatment on the fetus. UDCA has been studied in females with intrahepatic cholestasis of pregnancy and is well-tolerated and safe. Its use has been associated with relief of pruritus, decreased levels of endogenous bile acids, normalization of alanine aminotransferase levels, and improved fetal outcomes [<a href="#rid26">26-30</a>]. <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">Cholestyramine</a> and antihistamines are often ineffective and are not well tolerated in this population [<a href="#rid23">23,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy", section on 'Maternal treatment'</a>.)</p><p class="headingAnchor" id="H71723711"><span class="h4">Bile acid sequestrants</span><span class="headingEndMark"> — </span>The bile acid resins <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> and <a class="drug drug_general" data-topicid="9294" href="/z/d/drug information/9294.html" rel="external">colestipol</a> are effective first-line agents in the management of moderate to severe cholestatic pruritus based on their favorable safety profile and clinical experience [<a href="#rid32">32</a>]. The effective dose of cholestyramine ranges from 4 to 16 grams per day. Treatment typically begins with two 4-gram doses daily, with additional doses being added if needed. In patients who are also taking UDCA, bile acid sequestrants should be given two to four hours before or after ingestion of UDCA. Efficacy may be increased by administering a dose before and a dose after breakfast in patients with an intact gallbladder to enhance the excretion of the pruritogens, which presumably accumulate in the gallbladder during the overnight fast. If symptoms persist, the dose can be titrated upward by giving a dose after lunch and, if needed, a dose after dinner.</p><p>These drugs are nonabsorbable, basic polystyrenes that bind anions in the gut lumen, including bile acids. They lower bile acid levels by inhibiting the reabsorption of bile acids by approximately 90 percent. However, binding of bile acids alone is unlikely to explain their benefit, since a potent bile acid sequestrant (<a class="drug drug_general" data-topicid="8954" href="/z/d/drug information/8954.html" rel="external">colesevelam</a>) was not effective for cholestatic pruritus in a randomized trial [<a href="#rid33">33</a>]. They also decrease pruritus in noncholestatic disorders, such as uremia and polycythemia vera, suggesting that these resins bind other pruritogens. This may in part be due to the induction of cholecystokinin release, which is an endogenous anti-opioid [<a href="#rid34">34,35</a>].</p><p>There have been few randomized trials of <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> for cholestasis-associated pruritus [<a href="#rid22">22</a>]. Early studies suggested 80 to 85 percent of patients responded, either completely or partially, with a response maintained for 6 to 36 months. Improvement is often seen within a few weeks of starting treatment [<a href="#rid2">2</a>].</p><p>Medication adherence can be a significant problem with the use of bile acid resins. These drugs are unpalatable, induce constipation, and can interfere with the absorption of a number of medications including UDCA, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, and thiazide diuretics. They can also lead to fat malabsorption and vitamin K deficiency. As a result, patients should be monitored for vitamin K deficiency while receiving bile acid resins.</p><p class="headingAnchor" id="H71723914"><span class="h4">Rifampin</span><span class="headingEndMark"> — </span>Several reports have demonstrated improvement in cholestatic pruritus with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (also known as rifampicin) [<a href="#rid22">22,36-38</a>]. It is given as 150 to 300 mg twice daily. In a meta-analysis of five randomized crossover trials with 61 patients, during treatment with rifampin, 47 patients (77 percent) reported complete or partial resolution of pruritus, whereas 12 patients (20 percent) reported complete or partial resolution of pruritus while receiving placebo or alternative medication [<a href="#rid38">38</a>].</p><p><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> is a potent agonist of the pregnane X receptor (PXR), which mediates many detoxification and hepatobiliary processes. In addition, rifampin reduced autotaxin expression at the transcriptional level in a PXR-dependent manner in a study using human hepatoma cells [<a href="#rid20">20</a>]. This may explain the molecular mechanisms behind the anti-pruritogenic action of rifampicin in patients with pruritus associated with cholestasis. (See <a class="local">'Lysophosphatidic acid'</a> above.)</p><p>Adverse effects of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> include nausea, decreased appetite, hemolytic anemia, renal failure, and hepatitis [<a href="#rid22">22,39</a>]. Because of the risk of hepatitis, caution should be exercised with rifampin use in cholestatic conditions, and patients should have their serum aminotransferase monitored at regular intervals (eg, every three months).</p><p class="headingAnchor" id="H71723952"><span class="h4">Opioid antagonists</span><span class="headingEndMark"> — </span>Opioid antagonists such as intravenous <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> (given as a bolus of 0.4 mg followed by 0.2 mcg/kg per minute for 24 hours), oral <a class="drug drug_general" data-topicid="135038" href="/z/d/drug information/135038.html" rel="external">nalmefene</a> (60 to 120 mg daily), and oral <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> (12.5 to 50 mg daily) are often associated with substantial relief of cholestatic pruritus [<a href="#rid15">15,22,40-43</a>]. Opioid antagonists should not be used in patients receiving opioid-containing medications or in patients with acute hepatitis, liver failure, or severe liver dysfunction [<a href="#rid39">39</a>].</p><p>In a randomized crossover trial with 29 patients, <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> led to a 27 percent reduction in scratching activity and to a significant reduction in the perception of pruritus [<a href="#rid40">40</a>]. Similarly, a study of 16 patients randomly assigned to receive <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> or placebo found that the former was associated with a significant improvement in daytime itching (change in pruritus score -54 versus 8 percent), as well as nighttime itching (-44 versus 7 percent) [<a href="#rid41">41</a>]. Persistent benefits were observed for at least two months in a third randomized crossover trial with 20 patients [<a href="#rid43">43</a>]. Nine patients had a &gt;50 percent decrease in pruritus, and pruritus disappeared completely in five.</p><p>Opioid antagonists are generally well tolerated with the exception of a self-limited opioid withdrawal-like syndrome that usually resolves spontaneously within two days [<a href="#rid43">43</a>]. This problem may be more prominent with <a class="drug drug_general" data-topicid="135038" href="/z/d/drug information/135038.html" rel="external">nalmefene</a>, which is currently only available for experimental use [<a href="#rid42">42</a>]. The likelihood of a withdrawal syndrome may be decreased with a cautious initial intravenous infusion (such as <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> starting at 0.002 micrograms per kg/min, gradually increasing until reaching a therapeutic dose) followed by oral therapy [<a href="#rid44">44</a>]. In addition, opioid antagonists may lead to uncontrolled pain in patients who have various underlying causes of pain (eg, postherpetic neuralgia) [<a href="#rid45">45</a>]. As the role of endogenous opioids for cholestatic pruritus becomes better defined, the use of these agents, particularly the oral formulations, may become more widespread.</p><p class="headingAnchor" id="H71723992"><span class="h4">Sertraline</span><span class="headingEndMark"> — </span>Case series and a small controlled trial have suggested a possible benefit from selective serotonin reuptake inhibitors. <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">Sertraline</a> (75 to 100 mg daily) was effective in a retrospective analysis of a group of patients with primary biliary cholangitis who were participating in a trial of UDCA with and without <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid46">46</a>], and in a small randomized crossover trial of patients with pruritus due to various forms of liver disease [<a href="#rid47">47</a>]. <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">Paroxetine</a> was beneficial in a separate report of patients with severe non-dermatologic pruritus (most of whom had non liver disease-related causes) [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H71724015"><span class="h4">Antihistamines</span><span class="headingEndMark"> — </span>Antihistamines are commonly used for the treatment of pruritus in patients with cholestatic liver disease, though studies looking at their efficacy are lacking. Because of their sedating effects, antihistamines may be beneficial in patients who have insomnia as a result of their pruritus [<a href="#rid49">49</a>]. </p><p class="headingAnchor" id="H71724021"><span class="h4">Ursodeoxycholic acid</span><span class="headingEndMark"> — </span>UDCA is effective for treating pruritus in patients with intrahepatic cholestasis of pregnancy, and it may be effective for treating pruritus in primary biliary cholangitis where it is also used as part of the standard treatment for primary biliary cholangitis. However, the effect of UDCA on pruritus due to cholestatic disorders is unclear [<a href="#rid50">50</a>]. In terms of treating pruritus, we reserve UDCA for the treatment of patients with intrahepatic cholestasis of pregnancy or primary biliary cholangitis. UDCA is given as 13 to 15 mg/kg per day (given in two to three divided doses). (See  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy", section on 'Ursodeoxycholic acid'</a> and  <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">"Overview of the management of primary biliary cholangitis", section on 'Initial therapy'</a>.)</p><p>UDCA is a naturally occurring dihydroxy bile acid that, when administered exogenously, changes the bile acid pool to a more hydrophilic mix [<a href="#rid51">51,52</a>]. It is unclear if this effect is due to competition for intestinal absorption of endogenous bile acids or to increased hepatic clearance of endogenous bile acids. </p><p>In females with intrahepatic cholestasis of pregnancy, UDCA is well-tolerated and safe. Its use has been associated with relief or pruritus, decreased levels of endogenous bile acids, normalization of alanine aminotransferase levels, and improved fetal outcomes [<a href="#rid26">26-30</a>]. (See  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy", section on 'Ursodeoxycholic acid'</a>.)</p><p>Two large trials in primary biliary cholangitis showed no improvement in pruritus at a dose of 13 to 15 mg/kg per day [<a href="#rid53">53,54</a>]. By comparison, high-dose therapy (30 mg/kg per day in three divided doses) in another report led to relief of itching [<a href="#rid55">55</a>]. In the latter study, pruritus disappeared in six of seven patients within one month. Until more data become available, we do not recommend high-dose therapy for patients with primary biliary cholangitis.</p><p class="headingAnchor" id="H71723235"><span class="h3">Pruritus refractory to standard treatment</span><span class="headingEndMark"> — </span>In patients with moderate to severe pruritus that fails to improve adequately with standard treatment, consideration should be given to alternative treatments. Switching to <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> or <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> at bedtime can be tried if other measures fail. Phenobarbital has been effective in case series [<a href="#rid56">56,57</a>]. It can be given as 90 mg at bedtime, although it has the disadvantage of causing somnolence during the first few weeks of use. If medical treatments fail and the pruritus is severe, liver transplantation may be the only effective therapy. </p><p>Novel ileal bile acid transport (IBAT) inhibitors may be effective in reducing the severity of pruritus in patients with cholestasis by interrupting enterohepatic circulation of bile acids. In a randomized phase II crossover trial, 22 patients with pruritus associated with primary biliary cirrhosis were assigned to a selective inhibitor of human IBAT (GSK2330672) or placebo for two weeks [<a href="#rid58">58</a>]. Treatment with GSK2330672 was not associated with any serious side effects. Diarrhea was the most frequent treatment-related adverse event and was significantly higher in the treatment group as compared with placebo (7 versus 1) but did not require dose reduction or discontinuation. Treatment with GSK2330672 resulted in a significant reduction in total and conjugated bile acids and pruritus. However, larger studies of longer duration are needed to assess the efficacy of GSK2330672 in the treatment of pruritus in cholestasis.</p><p>Several other treatments have only been evaluated in case series, but their role in the routine treatment of cholestasis-associated pruritus is unclear:</p><p class="bulletIndent1"><span class="glyph">●</span>Phototherapy with ultraviolet light (UV-B) has been helpful in case reports [<a href="#rid59">59-61</a>]. The mechanism is unknown, although hypotheses include an alteration in skin sensitivity to pruritogens or a modification in bile salt turnover by mobilizing skin bile salts. In our experience, phototherapy has been unsuccessful in more than 80 percent of patients with primary biliary cholangitis who failed to respond to <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some studies have demonstrated relief of pruritus following plasmapheresis in patients with cholestasis [<a href="#rid62">62-64</a>]. However, clinical experience has been mixed. This technique is too cumbersome and expensive for routine use but may have a role when all else fails, particularly when a more definitive treatment is anticipated, such as in patients awaiting liver transplantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nasobiliary drainage was effective in a series of 27 patients who underwent 29 nasobiliary drainage procedures [<a href="#rid65">65</a>]. The median duration of nasobiliary drainage was seven days, and pruritus improved following 26 of the procedures (90 percent). However, 31 percent of procedures were associated with mild post-endoscopic retrograde cholangiopancreatography pancreatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">Propofol</a> was given to three patients at subhypnotic doses via intravenous infusion [<a href="#rid66">66</a>]. Marked improvement in pruritus was noted without disabling sedation. The proposed mechanism was inhibition of ventral and dorsal spinal nerve roots modulated by endogenous opioid-like ligands.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Androgens (such as norethandrolone, <a class="drug drug_general" data-topicid="9640" href="/z/d/drug information/9640.html" rel="external">methyltestosterone</a>, and stanozolol) increase serum bile acids and worsen jaundice, yet they paradoxically relieve pruritus in some patients with cholestasis [<a href="#rid67">67</a>]. How this occurs is not known, but multiple side effects limit the use of these drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delta-9-tetrahydrocannabinol (Marinol) was helpful in a case series of three patients [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Molecular Adsorbent Recirculating System (a hemofiltration device) has been effective in case series [<a href="#rid69">69-72</a>].</p><p></p><p class="headingAnchor" id="H829409846"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112041.html" rel="external">"Society guideline links: Primary biliary cholangitis"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus may develop in patients with cholestasis due to any cause, including primary biliary cholangitis (previously referred to as primary biliary cirrhosis), primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, biliary obstruction, chronic viral hepatitis, cirrhosis, prolonged drug-induced cholestasis, and inherited cholestasis syndromes. (See <a class="local">'Associated conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus in patients with cholestasis may be generalized or localized (particularly to the palms of the hands and soles of the feet). The intensity of the pruritus is variable and it can wax and wane spontaneously. The severity does not correlate with the severity of the underlying liver disease. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A presumptive diagnosis of cholestasis-associated pruritus can be made in a patient with cholestasis who complains of itching. An extensive evaluation is generally not required, provided the cause of the cholestasis is known, though patients should have a skin examination to look for evidence of dermatologic disorders associated with pruritus (eg, atopic dermatitis or contact dermatitis). (See <a class="local">'Diagnosis and differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The treatment of choice for pruritus associated with cholestasis is correction of the underlying hepatobiliary disease, when possible. If the underlying hepatobiliary disease cannot be corrected, treatment is aimed at the pruritus itself. The treatment chosen will depends on the severity of symptoms and the underlying disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For mild pruritus, we suggest general measures such as warm baths with or without an antihistamine (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Mild pruritus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with primary biliary cholangitis and moderate to severe pruritus, we suggest treatment with a bile acid sequestrant rather than an alternative medication (such as <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> or an opioid antagonist) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We also recommend treatment with <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a> (UDCA) rather than treating with a bile acid sequestrant alone (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). UDCA may improve pruritus in these patients and delays the progression to end-stage liver disease, enhances survival, and is well-tolerated. Bile acid sequestrants should be given two to four hours before or after ingestion of UDCA. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In females with intrahepatic cholestasis of pregnancy and moderate to severe pruritus, we suggest treatment with UDCA (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). UDCA has been studied in females with intrahepatic cholestasis of pregnancy and is well-tolerated and safe. Its use has been associated with relief or pruritus, decreased levels of endogenous bile acids, normalization of alanine aminotransferase levels, and improved fetal outcomes. (See <a class="local">'Ursodeoxycholic acid'</a> above and  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy", section on 'Ursodeoxycholic acid'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with moderate to severe pruritus who do not have primary biliary cholangitis or intrahepatic cholestasis of pregnancy, we suggest treatment with a bile acid sequestrant such as <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> or <a class="drug drug_general" data-topicid="9294" href="/z/d/drug information/9294.html" rel="external">colestipol</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Bile acid sequestrants'</a> above.)</p><p></p><p class="bulletIndent2">For patients who do not respond to or do not tolerate a bile acid sequestrant, we suggest the following approach (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>First, we switch to <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>. (See <a class="local">'Rifampin'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If symptoms persist, we then switch to an opioid antagonist, such as <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a>. Opioid antagonists are generally well tolerated with the exception of a self-limited opioid withdrawal-like syndrome that usually resolves spontaneously within two days. Opioid antagonists should not be used in patients receiving opioid-containing medications or in patients with acute hepatitis, liver failure, or severe liver dysfunction. (See <a class="local">'Opioid antagonists'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Switching to <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> or <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> at bedtime can be tried if other measures fail. Phenobarbital has the disadvantage of causing somnolence during the first few weeks of use. (See <a class="local">'Sertraline'</a> above and <a class="local">'Pruritus refractory to standard treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If medical treatments fail and the pruritus is severe, biliary diversion and liver transplantation may be the only effective therapy. (See <a class="local">'Pruritus refractory to standard treatment'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology 2022; 75:1012.</a></li><li><a class="nounderline abstract_t">Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012; 16:331.</a></li><li><a class="nounderline abstract_t">Beuers U, Wolters F, Oude Elferink RPJ. Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nat Rev Gastroenterol Hepatol 2023; 20:26.</a></li><li><a class="nounderline abstract_t">Düll MM, Kremer AE. Evaluation and Management of Pruritus in Primary Biliary Cholangitis. Clin Liver Dis 2022; 26:727.</a></li><li><a class="nounderline abstract_t">Thébaut A, Debray D, Gonzales E. An update on the physiopathology and therapeutic management of cholestatic pruritus in children. Clin Res Hepatol Gastroenterol 2018; 42:103.</a></li><li><a class="nounderline abstract_t">Schoenfield, L, Sjovall, J, Perman E. Bile acids on the skin of patients with pruritic hepatobiliary disease. Nature 1967; 213:93.</a></li><li><a class="nounderline abstract_t">Varadi DP. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. Arch Dermatol 1974; 109:678.</a></li><li><a class="nounderline abstract_t">Kirby J, Heaton KW, Burton JL. Pruritic effect of bile salts. Br Med J 1974; 4:693.</a></li><li><a class="nounderline abstract_t">Murphy GM, Ross A, Billing BH. Serum bile acids in primary biliary cirrhosis. Gut 1972; 13:201.</a></li><li><a class="nounderline abstract_t">Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus. Gastroenterology 1977; 73:1125.</a></li><li><a class="nounderline abstract_t">Ghent CN. Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. Am J Gastroenterol 1987; 82:117.</a></li><li><a class="nounderline abstract_t">Bergasa NV. Treatment of the Pruritus of Cholestasis. Curr Treat Options Gastroenterol 2004; 7:501.</a></li><li><a class="nounderline abstract_t">Thornton JR, Losowsky MS. Plasma leucine enkephalin is increased in liver disease. Gut 1989; 30:1392.</a></li><li><a class="nounderline abstract_t">Spivey J, Jorgensen R, Gores G, et al. Serum met-enkephalin levels in patients with primary biliary cirrhosis correlate with severity of disease but not pruritus. Gastroenterology 1992; 102:A892.</a></li><li><a class="nounderline abstract_t">Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988; 297:1501.</a></li><li><a class="nounderline abstract_t">Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979; 115:1366.</a></li><li><a class="nounderline abstract_t">Summerfield JA. Naloxone modulates the perception of itch in man. Br J Clin Pharmacol 1980; 10:180.</a></li><li><a class="nounderline abstract_t">Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010; 139:1008.</a></li><li><a class="nounderline abstract_t">Oude Elferink RP, Kremer AE, Martens JJ, Beuers UH. The molecular mechanism of cholestatic pruritus. Dig Dis 2011; 29:66.</a></li><li><a class="nounderline abstract_t">Kremer AE, van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012; 56:1391.</a></li><li><a class="nounderline abstract_t">Talbot TL, Schmitt JM, Bergasa NV, et al. Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrum Technol 1991; 25:400.</a></li><li><a class="nounderline abstract_t">Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102:1528.</a></li><li><a class="nounderline abstract_t">Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009; 15:2049.</a></li><li><a class="nounderline abstract_t">Corpechot C, Chazouillères O, Rousseau A, et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 2018; 378:2171.</a></li><li><a class="nounderline abstract_t">de Vries E, Bolier R, Goet J, et al. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial. Gastroenterology 2021; 160:734.</a></li><li><a class="nounderline abstract_t">Glantz A, Reilly SJ, Benthin L, et al. Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology 2008; 47:544.</a></li><li><a class="nounderline abstract_t">Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005; 129:894.</a></li><li><a class="nounderline abstract_t">Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997; 27:1022.</a></li><li><a class="nounderline abstract_t">Binder T, Salaj P, Zima T, Vítek L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med 2006; 34:383.</a></li><li><a class="nounderline abstract_t">Roncaglia N, Locatelli A, Arreghini A, et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG 2004; 111:17.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51:237.</a></li><li><a class="nounderline abstract_t">DATTA DV, SHERLOCK S. Treatment of pruritus of obstructive jaundice with cholestyramine. Br Med J 1963; 1:216.</a></li><li><a class="nounderline abstract_t">Kuiper EM, van Erpecum KJ, Beuers U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52:1334.</a></li><li><a class="nounderline abstract_t">Bergasa NV. The pruritus of cholestasis. J Hepatol 2005; 43:1078.</a></li><li><a class="nounderline abstract_t">Wiertelak EP, Maier SF, Watkins LR. Cholecystokinin antianalgesia: safety cues abolish morphine analgesia. Science 1992; 256:830.</a></li><li><a class="nounderline abstract_t">Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991; 36:216.</a></li><li><a class="nounderline abstract_t">Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94:488.</a></li><li><a class="nounderline abstract_t">Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006; 26:943.</a></li><li><a class="nounderline abstract_t">Imam MH, Gossard AA, Sinakos E, Lindor KD. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol 2012; 27:1150.</a></li><li><a class="nounderline abstract_t">Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123:161.</a></li><li><a class="nounderline abstract_t">Wolfhagen FH, Sternieri E, Hop WC, et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113:1264.</a></li><li><a class="nounderline abstract_t">Bergasa NV, Schmitt JM, Talbot TL, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27:679.</a></li><li><a class="nounderline abstract_t">Terg R, Coronel E, Sordá J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37:717.</a></li><li><a class="nounderline abstract_t">Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002; 95:547.</a></li><li><a class="nounderline abstract_t">McRae CA, Prince MI, Hudson M, et al. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003; 125:591.</a></li><li><a class="nounderline abstract_t">Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98:2736.</a></li><li><a class="nounderline abstract_t">Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45:666.</a></li><li><a class="nounderline abstract_t">Zylicz Z, Krajnik M, Sorge AA, Costantini M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003; 26:1105.</a></li><li><a class="nounderline abstract_t">Simons FE, Watson WT, Chen XY, et al. The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. J Clin Pharmacol 1989; 29:809.</a></li><li><a class="nounderline abstract_t">Talwalkar JA, Souto E, Jorgensen RA, Lindor KD. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003; 1:297.</a></li><li><a class="nounderline abstract_t">Batta AK, Salen G, Mirchandani R, et al. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol 1993; 88:691.</a></li><li><a class="nounderline abstract_t">Poupon RE, Chrétien Y, Poupon R, Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993; 17:599.</a></li><li><a class="nounderline abstract_t">Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19:1149.</a></li><li><a class="nounderline abstract_t">Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336:691.</a></li><li><a class="nounderline abstract_t">Matsuzaki Y, Tanaka N, Osuga T, et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol 1990; 85:15.</a></li><li><a class="nounderline abstract_t">Stellaard F, Bolt MG, Boyer JL, Klein PD. Phenobarbital treatment in primary biliary cirrhosis. Differences in bile acid composition between responders and nonresponders. J Lab Clin Med 1979; 94:853.</a></li><li><a class="nounderline abstract_t">Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975; 82:310.</a></li><li><a class="nounderline abstract_t">Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 2017; 389:1114.</a></li><li><a class="nounderline abstract_t">Hanid MA, Levi AJ. Phototherapy for pruritus in primary biliary cirrhosis. Lancet 1980; 2:530.</a></li><li><a class="nounderline abstract_t">Cerio R, Murphy GM, Sladen GE, MacDonald DM. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br J Dermatol 1987; 116:265.</a></li><li><a class="nounderline abstract_t">Bergasa NV, Link MJ, Keogh M, et al. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001; 96:1563.</a></li><li><a class="nounderline abstract_t">Lauterburg BH, Taswell HF, Pineda AA, et al. Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads. Lancet 1980; 2:53.</a></li><li><a class="nounderline abstract_t">Cohen LB, Ambinder EP, Wolke AM, et al. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985; 26:291.</a></li><li><a class="nounderline abstract_t">Alallam A, Barth D, Heathcote EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol 2008; 22:505.</a></li><li><a class="nounderline abstract_t">Hegade VS, Krawczyk M, Kremer AE, et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther 2016; 43:294.</a></li><li><a class="nounderline abstract_t">Borgeat A, Wilder-Smith O, Mentha G, Huber O. Propofol and cholestatic pruritus. Am J Gastroenterol 1992; 87:672.</a></li><li><a class="nounderline abstract_t">Walt RP, Daneshmend TK, Fellows IW, Toghill PJ. Effect of stanozolol on itching in primary biliary cirrhosis. Br Med J (Clin Res Ed) 1988; 296:607.</a></li><li><a class="nounderline abstract_t">Neff GW, O'Brien CB, Reddy KR, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002; 97:2117.</a></li><li><a class="nounderline abstract_t">Macia M, Avilés J, Navarro J, et al. Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. Am J Med 2003; 114:62.</a></li><li><a class="nounderline abstract_t">Doria C, Mandalá L, Smith J, et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl 2003; 9:437.</a></li><li><a class="nounderline abstract_t">Bellmann R, Graziadei IW, Feistritzer C, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004; 10:107.</a></li><li><a class="nounderline abstract_t">Parés A, Cisneros L, Salmerón JM, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99:1105.</a></li></ol></div><div id="topicVersionRevision">Topic 3607 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34431119" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541702" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pruritus in chronic cholestatic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36307649" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mechanisms of pruritus in cholestasis: understanding and treating the itch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36270726" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evaluation and Management of Pruritus in Primary Biliary Cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29031874" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : An update on the physiopathology and therapeutic management of cholestatic pruritus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bile acids on the skin of patients with pruritic hepatobiliary disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4828535" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4441863" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pruritic effect of bile salts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5024725" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Serum bile acids in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/908491" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3812415" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15527716" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of the Pruritus of Cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2583565" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Plasma leucine enkephalin is increased in liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Serum met-enkephalin levels in patients with primary biliary cirrhosis correlate with severity of disease but not pruritus</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3147046" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Opioid peptides and primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/389168" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Relief of intractable pruritus with naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7000110" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Naloxone modulates the perception of itch in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20546739" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lysophosphatidic acid is a potential mediator of cholestatic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21691108" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The molecular mechanism of cholestatic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473838" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1933091" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Application of piezo film technology for the quantitative assessment of pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403073" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19418576" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Intrahepatic cholestasis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29874528" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33031833" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17968976" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143129" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9453428" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16965225" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687046" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501929" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : EASL Clinical Practice Guidelines: management of cholestatic liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14025214" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of pruritus of obstructive jaundice with cholestyramine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20683930" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16253381" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The pruritus of cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1589765" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cholecystokinin antianalgesia: safety cues abolish morphine analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1988266" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of pruritus of primary biliary cirrhosis with rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3275568" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16953834" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22413872" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pathogenesis and management of pruritus in cholestatic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7598296" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9322521" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9500694" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12445410" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145394" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12891561" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pain as a complication of use of opiate antagonists for symptom control in cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687826" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17326161" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sertraline as a first-line treatment for cholestatic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14654262" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2572611" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15017671" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Natural history of pruritus in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8480734" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8477964" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8175136" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041099" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1967512" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/501209" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Phenobarbital treatment in primary biliary cirrhosis. Differences in bile acid composition between responders and nonresponders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1115464" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Phenobarbital effects in cholestatic liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28187915" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6105574" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Phototherapy for pruritus in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3828220" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11374700" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6105243" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3972276" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Role of plasmapheresis in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18478137" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26526892" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1595661" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Propofol and cholestatic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3126923" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of stanozolol on itching in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12190187" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12543292" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682899" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14755786" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180733" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
